Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.6K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K
Retroviruses02:33

Retroviruses

13.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
13.6K
Subviral Agents01:29

Subviral Agents

312
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
312
Viral Mutations00:36

Viral Mutations

37.7K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
37.7K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

416
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
416
Introduction to Virus01:28

Introduction to Virus

726
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
726

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

British journal of haematology·2026
Same author

Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer.

Cancer medicine·2026
Same author

Hepatitis B immunoglobulins after liver transplantation: essential early, optional later?

Gut·2026
Same author

Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review.

Biomedicines·2026
Same author

Clinical impact of molecular tumor board inclusion on treatment outcomes in neuroendocrine neoplasms.

Neuroendocrinology·2026
Same author

Development and validation of multivariable prognostic machine learning models to identify patients at risk for inadequate bowel preparation when undergoing colonoscopy: a prospective, multicentre study.

BMJ open gastroenterology·2026

Related Experiment Video

Updated: Nov 21, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K

[Viral hepatitis A-E].

Annegrit Decker1, Christoph Neumann-Haefelin1, Robert Thimme2

  • 1Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.

Der Internist
|January 14, 2021
PubMed
Summary

Hepatitis viruses A-E cause liver inflammation globally. Early screening and targeted therapies, including vaccines and antivirals, can prevent severe liver disease like cirrhosis and cancer.

Keywords:
Antiviral agents, direct actingHBV reactivationHepatitis, acuteHepatitis, chronicLiver cirrhosis

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.7K

Related Experiment Videos

Last Updated: Nov 21, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.7K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis viruses A-E are major global causes of liver inflammation, morbidity, and mortality.
  • These viruses exhibit diverse biological characteristics, disease progression, and treatment strategies.
  • While Hepatitis A and B are vaccine-preventable, Hepatitis C lacks a vaccine but is curable with new antivirals.

Purpose of the Study:

  • To summarize the clinical significance and management of Hepatitis viruses A-E.
  • To highlight the importance of early detection and specific therapies for viral hepatitis.
  • To emphasize the role of screening in preventing severe liver complications.

Main Methods:

  • Review of current knowledge on Hepatitis viruses A-E.
  • Analysis of disease characteristics, diagnostic markers, and therapeutic options.
  • Emphasis on serological screening for early diagnosis and intervention.

Main Results:

  • Hepatitis A causes acute infection; Hepatitis B can be chronic or reactivate, sometimes with Hepatitis D.
  • Hepatitis C, though lacking a vaccine, is curable with direct antiviral agents.
  • Hepatitis E often causes acute hepatitis, but can become chronic in immunosuppressed individuals.

Conclusions:

  • Continuous screening of at-risk populations and those with elevated liver enzymes is crucial.
  • Virus-specific therapies, enabled by serological markers, can manage asymptomatic chronic viral hepatitis.
  • Early intervention prevents progression to liver cirrhosis and hepatocellular carcinoma.